DAS-II GCA scores within cognitive development categories
deteriorating cognitive functioning
GCA
The one patient with above-average cognitive growth rates in DAS-II GCA scores (who received idursulfase-IT in the randomized trial) had an increasing trend in GCA score over the 2 years; there was a relatively flatter trend in GCA scores among patients with average cognitive growth rates in DAS-II GCA scores, and a decreasing trend in GCA scores in patients with below-average cognitive growth rates in DAS-II GCA scores, plateauing cognitive functioning, or deteriorating cognitive functioning (both treatment groups; Fig. DAS-II GCA score